• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ATEC Reports Fourth Quarter and Full Year 2024 Financial Results

    2/26/25 4:00:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    • Full year 2024 total revenue grew 27% to $612 million, enabling significant profit margin expansion
    • Full year 2025 total revenue expected to approximate $732 million and fuel free cash flow

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and year ended December 31, 2024, and business highlights.

    Fourth Quarter and Full Year 2024 Financial Results

    Quarter Ended December 31, 2024

    Year Ended December 31, 2024

    Total revenue

    $177 million

    $612 million

    GAAP gross margin

    69%

    69%

    Non-GAAP gross margin

    70%

    70%

    Operating expenses

    $145 million

    $560 million

    Non-GAAP operating expenses

    $119 million

    $461 million

    GAAP net loss

    ($33) million

    ($162) million

    Non-GAAP adjusted EBITDA

    $21 million

    $31 million

    Non-GAAP adjusted EBITDA margin

    12%

    5%

    Ending cash balance

    $139 million

    Numbers and percentages may not foot due to rounding.

    Fourth Quarter 2024 Business Highlights

    • Grew surgical revenue by 28%, with 19% surgical volume growth and a 7% increase in average revenue per surgery
    • Increased new surgeon users by 20%
    • Entered Japan with first surgery
    • Generated $9 million of free cash flow

    "As many in the industry are choosing to capitulate, ATEC, the largest pure-play spine company, remains focused on revolutionizing spine care," asserted Pat Miles, Chairman and Chief Executive Officer. "The coming years will be our best yet. We are expanding our influence in deformity through EOS-integrated, procedure-specific technologies. We are thrilled to have performed our first surgeries in Japan, the world's second-largest spine market. The durable revenue growth that we are driving, combined with sharpened operational discipline, position us for self-funded growth in 2025 and beyond."

    Financial Outlook for the Full Year 2025

    The Company continues to expect total revenue for the fiscal year ended December 31, 2025, to approximate $732 million, reflecting growth of approximately 20% compared to full year 2024. This includes surgical revenue of approximately $657 million and approximately $75 million of EOS revenue. The Company also continues to anticipate adjusted EBITDA of approximately $75 million, which will contribute to positive free cash flow for the full year 2025.

    Financial Results Webcast

    The Company will host a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website.

    To dial into the live webcast, please register at this link. Access details will be shared via email.

    Non-GAAP Financial Information

    To supplement the Company's financial statements presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company reports certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures and a discussion of the Company's non-GAAP definitions. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2025 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of 2025 adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

    About Alphatec Holdings, Inc.

    ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company's expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth and financial outlook; planned product launches, introductions, regulatory submissions or clearances and territory penetration; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

    Alphatec Holdings, Inc.

    Consolidated Statements of Operations

    (in thousands, except per share amounts)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Year Ended

     

     

    December 31,

     

    December 31,

     

     

    2024

     

    2023

     

    2024

     

    2023

    (unaudited)
    Revenue from products and services

    $

    176,793

     

    $

    137,970

     

    $

    611,562

     

    $

    482,262

     

    Cost of sales

     

    55,205

     

     

    42,780

     

     

    187,300

     

     

    172,059

     

    Gross profit

     

    121,588

     

     

    95,190

     

     

    424,262

     

     

    310,203

     

    Operating expenses:
    Research and development

     

    23,244

     

     

    22,284

     

     

    80,718

     

     

    70,115

     

    Sales, general and administrative

     

    114,541

     

     

    104,120

     

     

    450,199

     

     

    374,080

     

    Litigation-related expenses

     

    1,188

     

     

    9,472

     

     

    9,799

     

     

    22,287

     

    Amortization expense

     

    4,720

     

     

    3,823

     

     

    16,258

     

     

    14,284

     

    Transaction-related expenses

     

    327

     

     

    (65

    )

     

    210

     

     

    2,113

     

    Restructuring expenses

     

    1,386

     

     

    386

     

     

    3,247

     

     

    719

     

    Total operating expenses

     

    145,406

     

     

    140,020

     

     

    560,431

     

     

    483,598

     

    Operating loss

     

    (23,818

    )

     

    (44,830

    )

     

    (136,169

    )

     

    (173,395

    )

    Other expense, net:
    Interest expense, net

     

    (7,151

    )

     

    (4,416

    )

     

    (24,879

    )

     

    (16,641

    )

    Other (expense) income, net

     

    (1,922

    )

     

    44

     

     

    (1,025

    )

     

    3,121

     

    Total other expense, net

     

    (9,073

    )

     

    (4,372

    )

     

    (25,904

    )

     

    (13,520

    )

    Net loss before taxes

     

    (32,891

    )

     

    (49,202

    )

     

    (162,073

    )

     

    (186,915

    )

    Income tax benefit

     

    441

     

     

    (124

    )

     

    50

     

     

    (277

    )

    Net loss

    $

    (33,332

    )

    $

    (49,078

    )

    $

    (162,123

    )

    $

    (186,638

    )

    Net loss per share, basic and diluted

    $

    (0.23

    )

    $

    (0.37

    )

    $

    (1.13

    )

    $

    (1.54

    )

    Weighted average shares outstanding, basic and diluted

     

    144,583

     

     

    133,750

     

     

    142,946

     

     

    121,242

     

    Stock-based compensation included in:
    Cost of sales

    $

    2,485

     

    $

    481

     

    $

    4,961

     

    $

    25,082

     

    Research and development

     

    9,894

     

     

    9,154

     

     

    27,030

     

     

    18,741

     

    Sales, general and administrative

     

    9,154

     

     

    10,880

     

     

    41,286

     

     

    37,421

     

    $

    21,533

     

    $

    20,515

     

    $

    73,277

     

    $

    81,244

     

    Alphatec Holdings, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands)
     
    December 31,

    2024
    December 31,

    2023
     
    ASSETS
    Current assets:
    Cash and cash equivalents

    $

    138,840

     

    $

    220,970

    Accounts receivable, net

     

    82,987

     

     

    72,613

    Inventories

     

    175,264

     

     

    136,842

    Prepaid expenses and other current assets

     

    20,308

     

     

    20,666

    Total current assets

     

    417,399

     

     

    451,091

    Property and equipment, net

     

    156,394

     

     

    149,835

    Right-of-use assets

     

    34,701

     

     

    26,410

    Goodwill

     

    70,976

     

     

    73,003

    Intangible assets, net

     

    93,518

     

     

    102,451

    Other assets

     

    2,722

     

     

    2,418

    Total assets

    $

    775,710

     

    $

    805,208

     
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable

    $

    52,984

     

    $

    48,985

    Accrued expenses and other current liabilities

     

    81,466

     

     

    87,712

    Contract liabilities

     

    10,467

     

     

    13,910

    Short-term debt

     

    1,656

     

     

    1,808

    Current portion of operating lease liabilities

     

    6,453

     

     

    5,159

    Total current liabilities

     

    153,026

     

     

    157,574

    Total long-term liabilities

     

    613,250

     

     

    545,915

    Redeemable preferred stock

     

    23,603

     

     

    23,603

    Stockholders' equity

     

    (14,169

    )

     

    78,116

    Total liabilities and stockholders' equity

    $

    775,710

     

    $

    805,208

     

    Alphatec Holdings, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (in thousands)

     

     

     

     

     

     

     

    Three Months Ended

     

    Year Ended

     

     

    December 31,

     

    December 31,

     

     

    2024

     

    2023

     

    2024

     

    2023

    (unaudited)
    Gross profit, GAAP

    $

    121,588

     

    $

    95,190

     

    $

    424,262

     

    $

    310,203

     

    Add: amortization of intangible assets

     

    (814

    )

     

    278

     

     

    108

     

     

    939

     

    Add: stock-based compensation

     

    2,485

     

     

    481

     

     

    4,961

     

     

    25,082

     

    Add: purchase accounting adjustments on acquisitions

     

    —

     

     

    198

     

     

    197

     

     

    393

     

    Non-GAAP gross profit

    $

    123,259

     

    $

    96,147

     

    $

    429,528

     

    $

    336,617

     

    Gross margin, GAAP

     

    68.8

    %

     

    69.0

    %

     

    69.4

    %

     

    64.3

    %

    Add: amortization of intangible assets

     

    -0.5

    %

     

    0.2

    %

     

    0.0

    %

     

    0.2

    %

    Add: stock-based compensation

     

    1.4

    %

     

    0.3

    %

     

    0.8

    %

     

    5.2

    %

    Add: purchase accounting adjustments on acquisitions

     

    0.0

    %

     

    0.1

    %

     

    0.0

    %

     

    0.1

    %

    Non-GAAP gross margin

     

    69.7

    %

     

    69.7

    %

     

    70.2

    %

     

    69.8

    %

     

    Three Months Ended

     

    Year Ended

    December 31,

     

    December 31,

    2024

     

    2023

     

    2024

     

    2023

    (unaudited)
    Operating expenses, GAAP

    $

    145,406

     

    $

    140,020

     

    $

    560,431

     

    $

    483,598

     

    Adjustments:
    Stock-based compensation

     

    (19,048

    )

     

    (20,034

    )

     

    (68,316

    )

     

    (56,162

    )

    Litigation-related expenses

     

    (1,188

    )

     

    (9,472

    )

     

    (9,799

    )

     

    (22,287

    )

    Amortization expense

     

    (4,720

    )

     

    (3,823

    )

     

    (16,258

    )

     

    (14,284

    )

    Transaction-related expenses

     

    (327

    )

     

    65

     

     

    (210

    )

     

    (2,113

    )

    Restructuring expenses

     

    (1,386

    )

     

    (386

    )

     

    (3,247

    )

     

    (719

    )

    Other non-recurring expenses1, 2

     

    —

     

     

    —

     

     

    (1,608

    )

     

    (1,349

    )

    Non-GAAP operating expenses

    $

    118,737

     

    $

    106,370

     

    $

    460,993

     

    $

    386,684

     

     

    Three Months Ended

     

    Year Ended

    December 31,

     

    December 31,

    2024

     

    2023

     

    2024

     

    2023

    (unaudited)
    Net loss, GAAP

    $

    (33,332

    )

    $

    (49,078

    )

    $

    (162,123

    )

    $

    (186,638

    )

    Interest expense, net

    $

    7,151

     

    $

    4,416

     

    $

    24,879

     

    $

    16,641

     

    Other expense (income), net

     

    1,922

     

     

    (44

    )

     

    1,025

     

     

    (3,121

    )

    Income tax benefit

     

    441

     

     

    (124

    )

     

    50

     

     

    (277

    )

    Depreciation

     

    16,102

     

     

    11,918

     

     

    62,052

     

     

    40,916

     

    Amortization expense

     

    3,906

     

     

    4,101

     

     

    16,366

     

     

    15,223

     

    EBITDA

     

    (3,810

    )

     

    (28,811

    )

     

    (57,751

    )

     

    (117,256

    )

    Add back significant items:
    Stock-based compensation

     

    21,533

     

     

    20,515

     

     

    73,277

     

     

    81,244

     

    Purchase accounting adjustments on acquisitions

     

    —

     

     

    198

     

     

    197

     

     

    393

     

    Litigation-related expenses

     

    1,188

     

     

    9,472

     

     

    9,799

     

     

    22,287

     

    Transaction-related expenses

     

    327

     

     

    (65

    )

     

    210

     

     

    2,113

     

    Restructuring expenses

     

    1,386

     

     

    386

     

     

    3,247

     

     

    719

     

    Other non-recurring expenses1, 2

     

    —

     

     

    —

     

     

    1,608

     

     

    1,349

     

    Adjusted EBITDA

    $

    20,624

     

    $

    1,695

     

    $

    30,587

     

    $

    (9,151

    )

     
    Adjusted EBITDA margin

     

    11.7

    %

     

    1.2

    %

     

    5.0

    %

     

    (1.9

    %)

    Adjusted EBITDA margin expansion 1,050 bps
     
    1 Non-recurring net charges on assets and liabilities associated with customer plan of reorganization

    2

    Non-recurring consulting fees associated with the implementation of our state tax-planning strategy

    Non-GAAP Definitions

    Amortization of intangible assets: Represents amortization expense associated with intangible assets including, but not limited to customer relationships, intellectual property, and trade names acquired in business combinations and asset acquisitions.

    Litigation-related expenses: We are involved in various litigation matters that from time-to-time result in settlements. Litigation matters can vary in their characteristics, frequency and significance to our operating results and core business operations. We review litigation matters from both a qualitative and quantitative perspective to determine whether such matters are a normal and recurring part of our business. We include in our GAAP financial statements litigation fees and settlement expenses that we determine to be normal, recurring and routine to our business. When we determine that certain litigation matters are not normal and recurring to our core business operations, we believe excluding these expenses will provide our management and investors with useful incremental information. Litigation fees and settlement expenses excluded from our non-GAAP financial measures in the periods presented relate primarily to patent litigation and other litigation matters that relate directly to the business transformation that we started in 2018 and are discussed more fully in our periodic reports filed with the Securities Exchange Commission.

    Other non-recurring expenses: These expenses represent non-recurring expenses that we consider to be one-time in nature.

    Purchase accounting adjustments on acquisitions: Includes non-cash expenses incurred as a result of fair value asset step-ups associated with tangible assets acquired from business combinations or asset acquisitions.

    Restructuring expenses: From time-to-time, in order to realign the Company's operations or to achieve synergies associated with an acquisition, the Company may eliminate roles or restructure its operations and footprint. In such cases the Company may incur one-time severance and personnel costs associated with workforce reductions, or costs associated with exiting and/or relocating facilities. We exclude these costs as we do not consider such amounts to be part of the ongoing operations.

    Stock-based compensation: Stock-based compensation is charged to cost of revenue and operating expenses. We exclude stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding these non-cash expenses provides meaningful supplemental information regarding operational performance. Because of the variety of equity awards used by companies, the varying methodologies for determining stock-based compensation expense, the subjective assumptions involved in those determinations, and the volatility in valuations that can be driven by market conditions outside the Company's control, the Company believes excluding stock-based compensation expense enhances the ability of management and investors to understand and assess the underlying performance of its business over time.

    Transaction-related expenses: These expenses represent one-time costs associated with business combinations, asset acquisitions, and financings. These items may include but are not limited to consulting and legal fees, contract termination costs and other related deal costs.

    Adjusted EBITDA: Represents earnings before non-operating income/expense, taxes, depreciation and amortization, as adjusted for the applicable non-GAAP adjustments previously described.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250226053646/en/

    Investor/Media Contact:

    Tina Jacobsen, CFA

    Investor Relations

    (760) 494-6790

    [email protected]

    Company Contact:

    J. Todd Koning

    Chief Financial Officer

    [email protected]

    Get the next $ATEC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    10/12/2022$12.00Buy
    Jefferies
    9/12/2022$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance

      Surgical revenue grew 24%; total revenue grew 22% Full-year revenue and profitability guidance increased Successfully refinanced convertible debt to 2030 maturity Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corporate highlights. First Quarter 2025 Financial Results   Quarter Ended March 31, 2025 Total revenue $169 million GAAP gross margin 69% Non-GAAP gross margin 70% GAAP operating expenses $160 million Non-GAAP operating expenses $124 million GAAP net income /

      5/1/25 4:05:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system. This milestone marks the continued evolution of ATEC's PTP surgical approach, expanding its capabilities to include deformity and corpectomy procedures for complex pathologies of the thoracolumbar spine. "PTP Corpectomy represents a significant step forward in ATEC's commitment to improving patient outcomes in the most complex spine surgeries," said Pat Miles, Chairman and Chief Executive Officer. "By integrating advanced surgical techniques within a fully proceduralized

      4/21/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    SEC Filings

    See more
    • SEC Form S-8 filed by Alphatec Holdings Inc.

      S-8 - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:46:41 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:03:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Alphatec Holdings Inc.

      144 - Alphatec Holdings, Inc. (0001350653) (Subject)

      6/11/25 11:15:31 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on Alphatec with a new price target

      Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

      6/16/25 8:53:19 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec downgraded by Morgan Stanley

      Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight

      8/1/24 3:06:35 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Barclays initiated coverage on Alphatec with a new price target

      Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

      7/8/24 7:34:11 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Lish Scott sold $251,588 worth of shares (22,727 units at $11.07), decreasing direct ownership by 3% to 748,918 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/17/25 6:00:06 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Woods Ward W Jr was granted 15,131 shares, increasing direct ownership by 11% to 154,291 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:17 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Valentine Keith was granted 15,131 shares, increasing direct ownership by 18% to 97,271 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:16 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:32:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:27:25 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Demski David M bought $283,500 worth of shares (50,000 units at $5.67), increasing direct ownership by 21% to 288,441 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/21/24 10:00:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

      Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

      4/4/24 9:05:00 AM ET
      $ATEC
      $SYK
      Medical/Dental Instruments
      Health Care
    • John Booth to Retire as CEO of Spineology Inc.

      Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the

      11/9/23 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Financials

    Live finance-specific insights

    See more
    • ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2025 financial results on May 1, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducemen

      4/14/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Third Quarter Financial Results on October 30, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu

      10/7/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Second Quarter Financial Results on July 31, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

      7/10/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      11/12/24 8:04:57 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      3/22/24 7:57:56 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      5/12/23 4:51:18 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care